The important role that apoCIII plays as an LPL inhibitor as well as the findings from studies on animal and human loss of function have also shown the potential use of apoCIII inhibitors as a treatment approach for hypertriglyceridemia (27, 30, 95). This evidence concerns the gene LPL and hypertriglyceridemia.